Pricing Log in Create free account
Saturday 31 October 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.

170.84 5.23 +3.16%
Market cap
$205.4B
P/E
0.0×
Fwd P/E
−45.5×
Dividend yield
1.90%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Gilead Sciences, Inc. (GILD) EV/Sales

Alert me on EV/Sales

As of 30 October 2026, Gilead Sciences, Inc. (GILD) trades at a EV/Sales of 7.7×. Over the past ten years it has ranged from 3.3× (June 2017) to 7.7× (October 2026) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 4.3× and above the Healthcare sector median of 3.6×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 5.8× 25.86%
FY2024 4.6× 1.22%
FY2023 4.5× (2.79%)
FY2022 4.7× 13.31%
FY2021 4.1× 3.20%
FY2020 4.0× 6.84%
FY2019 3.7× 3.92%
FY2018 3.6× (11.08%)
FY2017 4.0× 6.96%
FY2016 3.8× (20.99%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 5.9× (6.28%)
Mar 2026 6.3× 9.29%
Dec 2025 5.8× 7.95%
Sep 2025 5.3× (2.15%)
42 more quarters

Against its own ten years

Low 3.3× High 7.7×
Ten-year median 4.2×
Current reading's percentile 100

EV/Sales against peers

Company EV/Sales
SNY Sanofi compare 2.2×
BMY Bristol Myers Squibb Company compare 3.2×
PFE Pfizer Inc. compare 3.5×
NVO Novo Nordisk A/S compare 3.7×
AZN AstraZeneca PLC compare 5.1×
NVS Novartis AG compare 6.1×
MRK Merck & Co., Inc. compare 6.2×
GILD Gilead Sciences, Inc. 7.7×
AMGN Amgen Inc. compare 7.7×
Drug Manufacturers General industry median 4.3×
Healthcare sector median 3.6×
Market median 2.2×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on GILD